Enzalutamide + Exemestane
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Breast Cancer ER+ve
Conditions
Primary Breast Cancer ER+ve, Primary Breast Cancer AR+ve TNBN
Trial Timeline
Aug 10, 2015 → Dec 31, 2016
NCT ID
NCT02676986About Enzalutamide + Exemestane
Enzalutamide + Exemestane is a phase 2 stage product being developed by Astellas Pharma for Primary Breast Cancer ER+ve. The current trial status is completed. This product is registered under clinical trial identifier NCT02676986. Target conditions include Primary Breast Cancer ER+ve, Primary Breast Cancer AR+ve TNBN.
What happened to similar drugs?
20 of 20 similar drugs in Primary Breast Cancer ER+ve were approved
Approved (20) Terminated (6) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02676986 | Phase 2 | Completed |
Competing Products
20 competing products in Primary Breast Cancer ER+ve